Dysregulation of HDAC2 and HDAC5 can be found in ER+, estrogen-independent, tamoxifen-resistant breast cancer cells and high expression of HDAC2 correlates with poor clinical outcomes in ER+ tamoxifen-treated breast cancer patients. Here, HDAC5 is linked to breast carcinoma.